2022
N. Lu et al. / Tetrahedron 63 (2007) 2019–2023
4. Experimental
bpy–CH2), 4.04 (4H, t, 3JHF¼13.5 Hz, CF2CH2); 19F NMR
(470.5 MHz, CDCl3) d ꢂ80.8 (3F), ꢂ119.3 (2F), ꢂ121.9
(6F), ꢂ122.7 (2F), ꢂ123.2 (2F), ꢂ126.1 (2F); 13C NMR
(113 MHz, CDCl3) d 73.0 (bpy–CH2), 67.7 (CH2CF2),
119.2, 121.9, 146.9, 149.6, 156.1 (bpy), 108.0–119.0
(C8F17); GC/MS (m/z; EI): 632 (M+ꢂOCHC8F17), 198
(C5H3NCH2C5H3NCH2O+), 183 (C5H3NCH2C5H3NCH+3),
91 (C5H3NCH+2); FTIR (cmꢂ1): 1602.0, 1559.8, 1465.0
(nbpy, m), 1203.7, 1144.7 (nCF2, vs); mp: 113–115 ꢀC.
4.1. General procedures
Gas chromatographic/mass spectrometric data were obtained
using an Agilent 6890 Series gas chromatograph with a series
5973 mass selective detector. The reaction was monitored
with an HP 6890 GC using a 30 mꢁ0.250 mm HP-1 capillary
column with a 0.25 mm stationary phase film thickness.
Temperature program was a 2 min hold at 50 ꢀC and then
taken to 260 ꢀC at 10 ꢀC/min and held for 12 min at
260 ꢀC. The flow rate was 1 mL/min and splitless. Infrared
spectra were obtained on a Perkin Elmer RX I FT-IR Spec-
trometer. NMR spectra were recorded on Bruker AM 500
and Joel AM 200 spectrometers using 5 mm sample tubes.
CD3OD, CD2Cl2, CD3Cl, and deuterated Me2SO were the
4.3.3. Compound 1c. NMR data were collected in CDCl3
at 60 ꢀC to increase the solubility. Yield (sublimed) 65%;
3
1H NMR (500 MHz, CDCl3) d 8.69 (2H, d, JHH¼5.1 Hz,
3
H6), 8.40 (2H, s, H3), 7.38 (2H, d, JHH¼4.2 Hz, H5), 4.80
3
(4H, s, bpy–CH2), 4.06 (4H, t, JHF¼13.3 Hz, CF2CH2);
19F NMR (470.5 MHz, CDCl3) d ꢂ80.7 (3F), ꢂ119.3
(2F), ꢂ121.7 (6F), ꢂ121.8 (4F), ꢂ122.6 (2F), ꢂ123.1
(2F), ꢂ126.0 (2F); 13C NMR (113 MHz, CDCl3) d 73.1
(bpy–CH2), 68.1 (CH2CF2), 119.8, 122.2, 144.7, 149.4,
154.1 (bpy), 105.5–116.2 (C10F21); GC/MS (m/z; EI): 732
(M+ꢂOCHC10F21), 198 (C5H3NCH2C5H3NCH2O+), 183
(C5H3NCH2C5H3NCH+3), 91 (C5H3NCH2+); FTIR (cmꢂ1):
1602.4, 1561.7 (nbpy, m), 1215.0, 1150.5 (nCF2, vs); mp:
140–142 ꢀC.
1
references for both H and 13C NMR spectra and FreonÒ
11 (CFCl3) was the reference for 19F NMR spectra. Thermo-
gravimetric analyses (TGA) were performed on a TA Instru-
ments TGA51.
4.2. Starting materials
Chemicals, reagents, and solvents employed were commer-
cially available and used as received. HCF2(CF2)7CH2OH
was obtained from Daikin Taiwan. C8F17CH2OH and
C10F21CH2OH were purchased from Aldrich and SynQuest.
4.4. Preparation of Pd complexes 2a–c where
Rf¼HCF2(CF2)7 (a), n-C8F17 (b), n-C10F21 (c)
4.3. Preparation of 4,40-bis(RfCH2OCH2)-2,20-bpy 1a–c
where Rf¼HCF2(CF2)7 (a), n-C8F17 (b), n-C10F21 (c)
Equimolar [PdCl2(CH3CN)2] (134.9 mg, 0.52 mmol) and
respective ligands 1a–c (0.52 mmol) in different reactions
were charged into a round-bottomed flask, and CH2Cl2
(3 mL) added as solvent. The color of the solution changed
from red to yellow after mixing for several minutes. The so-
lution was further stirred at room temperature for 24 h before
the solvents and volatiles were removed under vacuum. The
resulting yellow solids were collected as spectroscopically
pure products.
General procedure: 30% CH3ONa/CH3OH (1.1 g) and
RfCH2OH (6.0 mmol) were charged into a round-bottomed
flask, then continuously stirred under N2 atmosphere at
65 ꢀC for 4 h before CH3OH was vacuum removed to drive
the reaction to the fluorinated alkoxide side. The resultant
fluorinated alkoxide (6.0 mmol) was then dissolved in 20 mL
of dry CH3CN (or HFE 7100), and 4,40-bis(BrCH2)-2,20-
bpy (5.8 mmol) was added. The mixture was refluxed for
4 h, and the completion of the reaction was checked by
sampling the reaction mixtures and analyzing the aliquots
with GC/MS. The product was purified by vacuum sublima-
tion to obtain white solids. The vacuum level was 0.1 Torr,
and the sublimation temperature was 50 ꢀC above its mp.
4.4.1. Compound 2a. Yield 96%; 1H NMR (500 MHz,
3
Me2SO-d) d 9.08 (2H, d, JHH¼5.8 Hz, H6), 8.34 (2H, s,
3
H3), 7.73 (2H, dd, JHH¼5.8 Hz, H5), 7.19 (2H, tt,
3
2JHF¼50.3 Hz, JHF¼5.3 Hz, CF2H), 4.96 (4H, s, bpy–
3
CH2), 4.41 (4H, t, JHF¼14.6 Hz, CF2CH2); 19F NMR
(470.5 MHz, Me2SO-d) d ꢂ119.1 (s, 2F, CH2CF2), ꢂ121.9
(s, 6F), ꢂ122.9 (s, 4F), ꢂ128.7 (s, 2F, HCF2CF2), ꢂ138.5
(d, 2F, 2JHF¼52 Hz, HCF2); 13C NMR (113 MHz, Me2SO-
d) d 71.0 (bpy–CH2), 66.8 (CH2CF2), 120.5, 124.2, 149.3,
151.6, 155.6 (bpy), 105.0–116.4 (CF2)8; FTIR (cmꢂ1):
1654.0, 1559.9 (nbpy, m), 1209.9, 1146.9 (nCF2, vs);
HRMS (FAB): (M+; m/z¼) C30N2H16F32O2Pd35Cl2 calcd
1219.9113, found 1219.9169; C30N2H16F32O2Pd35Cl37Cl
calcd 1221.9041, found 1221.9041; C30N2H16F32O2Pd37Cl2
calcd 1223.9054, found 1223.9009.
4.3.1. Compound 1a. Yield (sublimed) 85%; 1H NMR
3
(500 MHz, CDCl3) d 8.69 (2H, d, JHH¼4.5 Hz, H6), 8.33
3
(2H, s, H3), 7.36 (2H, d, JHH¼4.5 Hz, H5), 6.03 (1H, tt,
3
2JHF¼51.9 Hz, JHF¼5.5 Hz, CF2H), 4.78 (4H, s, bpy–
3
CH2), 4.04 (4H, t, JHF¼13.7 Hz, CF2CH2); 19F NMR
(470.5 MHz, CDCl3) d ꢂ119 (s, 2F, CH2CF2), ꢂ121 (s,
6F), ꢂ123 (s, 4F), ꢂ129 (s, 2F, HCF2CF2–), ꢂ137 (d, 2F,
2JHF¼52 Hz, HCF2–); 13C NMR (113 MHz, CDCl3)
d 72.4 (bpy–CH2), 67.1 (CH2CF2), 118.9, 122.5, 147.9,
149.9, 155.7 (bpy), 105.0–116.3 (CF2)8; GC/MS (m/z; EI):
614 (M+ꢂOCH2C8F16), 198 (C5H3NCH2C5H3NCH2O+),
183 (C5H3NCH2C5H3NCH+3), 91 (C5H3NCH2+); FTIR
(cmꢂ1): 1595.6, 1558.3 (nbpy, m), 1208.3, 1140.3 (nCF2,
vs); mp: 86–88 ꢀC.
4.4.2. Compound 2b. NMR data were collected in DMF-d
at 90 ꢀC because of solubility. Yield 96%; 1H NMR
3
(500 MHz, DMF-d) d 9.29 (2H, d, JHH¼5.9 Hz, H6), 8.48
3
(2H, s, H3), 7.82 (2H, d, JHH¼5.9 Hz, H5), 5.08 (4H, s,
3
bpy–CH2), 4.47 (4H, t, JHF¼14.3 Hz, C8F17–CH2);
19F NMR (470.5 MHz, DMF-d) d ꢂ80.9 (3F), ꢂ119.1
(2F), ꢂ121.3 (6F), ꢂ122.1 (2F), ꢂ122.7 (2F), ꢂ125.5
(2F); 13C NMR (113 MHz, DMF-d) d 72.4 (bpy–CH2),
68.3 (CH2CF2), 121.7, 125.3, 15.6, 153.1, 157.2 (bpy),
4.3.2. Compound 1b. Yield (sublimed) 80%; 1H NMR
3
(500 MHz, CDCl3) d 8.67 (2H, d, JHH¼4.9 Hz, H6), 8.40
3
(2H, s, H3), 7.34 (2H, d, JHH¼4.9 Hz, H5), 4.77 (4H, s,